Tea Pribić
Research Subjects
Research Interests
Tea Pribić has a total of 111 co-authors. Here are the top co-authors by number of shared publications:
- Gordan Lauc
Genos Ltd., 10000 Zagreb, Croatia
7 shared publications - Irena Trbojević-Akmačić
Genos Glycoscience Research Laboratory, Zagreb, Croatia
4 shared publications - Azra Frkatović-Hodžić
Genos Glycoscience Research Laboratory
3 shared publications - Frano Vučković
Genos Glycoscience Research Laboratory, Zagreb, Croatia
3 shared publications Damir Marjanović
Institute for Anthropological Research, Zagreb, Croatia
2 shared publications- Wei Wang
Edith Cowan University
2 shared publications
Latest Publications
- Open Access
Impact of Antidiabetic Medications on IgG and Plasma Protein N-Glycosylation in Type 2 Diabetes Patients
Introduction: Diabetes is a growing global health challenge, necessitating effective management strategies. Glycosylation, a highly regulated post-translational protein modification, has emerged as a pivotal factor in diabetes pathophysiology. However, the modulation of protein glycosylation by antidiabetic treatment is still largely unknown. This study explored the longitudinal effects of four distinct antidiabetic therapies – metformin, insulin, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and glucagon-like peptide-1 receptor agonists (GLP-1RA) – on plasma protein and immunoglobulin G (IgG) glycosylation in patients with type 2 diabetes (T2D). Research Design and Methods: Plasma protein and IgG N-glycans were enzymatically released, purified and chromatographically profiled in a cohort of 124 patients, examined at four time points, to assess therapy-induced glycan alterations. Linear mixed models adjusting for covariates and multiple testing (FDR<0.05) were used to investigate the associations between plasma protein and IgG N-glycosylation and antidiabetic therapy. Results: Our findings reveal that metformin, SGLT2 inhibitors, and GLP-1RA induce significant alterations in IgG glycosylation, including the increased core fucosylation and galactosylation, features associated with a reduced inflammatory IgG potential. Notably, IgG monogalactosylation, previously linked to cardioprotective effects in women, was elevated in response to GLP-1RA and SGLT2 inhibitor treatments. Plasma protein glycosylation changes were more limited, with distinct alterations observed for each therapy. Metformin and GLP-1RA similarly reduced certain fucosylated and sialylated glycans, while SGLT2 inhibitors decreased a high-mannose glycan, previously positively associated with diabetes progression. Insulin therapy had a minimal effect on protein glycosylation, with only one plasma glycan significantly altered. Conclusions: Our findings emphasise the importance of protein glycosylation as a dynamic and responsive marker in T2D treatment. The distinct glycan alterations observed in response to metformin, SGLT2 inhibitors, and GLP-1 receptor agonists provide novel insights into the molecular effects of these therapies, potentially contributing to the development of glycan-based biomarkers for personalized diabetes management. What is already known on this topic?: ✓ Protein glycosylation is known to regulate multiple processes related to glucose homeostasis. ✓ Previous studies have shown that the IgG and plasma protein N-glycome (the entire set of N-glycans covalently attached to the IgG and plasma proteins, respectively) can help identify individuals at increased cardiometabolic risk. ✓ Despite most T2D patients receiving antidiabetic treatment, research on its effects on protein glycosylation remains scarce. What this study adds?: ✓ It is the first study to explore the effects of SGLT2 inhibitor and GLP-1RA therapy on protein glycosylation. ✓ The cardioprotective effects of these drug classes were also reflected in IgG glycosylation, demonstrated by increased monogalactosylation. ✓ Metformin, SGLT2 inhibitors, and GLP-1RA induce significant increase in IgG core fucosylation, a feature associated with reduced inflammatory IgG potential, possibly suggesting a shared pathway in suppressing inflammatory response. How this study might affect research, practice or policy?: ✓ The observed alterations in protein glycosylation across different therapeutic groups highlight its dynamic nature in response to metabolic interventions. ✓ Given the role of glycans in modulating immune function and inflammation, these findings suggest that glycan alterations could serve as potential biomarkers for assessing therapeutic response and disease progression in T2D. ✓ Future studies involving protein glycosylation should account for the potential confounding effects of antidiabetic medications to ensure accurate interpretations.
Open AccessImpact of Antidiabetic Medications on IgG and Plasma Protein N-Glycosylation in Type 2 Diabetes Patients
Introduction: Diabetes is a growing global health challenge, necessitating effective management strategies. Glycosylation, a highly regulated post-translational protein modification, has emerged as a pivotal factor in diabetes pathophysiology. However, the modulation of protein glycosylation by antidiabetic treatment is still largely unknown. This study explored the longitudinal effects of four distinct antidiabetic therapies – metformin, insulin, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and glucagon-like peptide-1 receptor agonists (GLP-1RA) – on plasma protein and immunoglobulin G (IgG) glycosylation in patients with type 2 diabetes (T2D). Research Design and Methods: Plasma protein and IgG N-glycans were enzymatically released, purified and chromatographically profiled in a cohort of 124 patients, examined at four time points, to assess therapy-induced glycan alterations. Linear mixed models adjusting for covariates and multiple testing (FDR<0.05) were used to investigate the associations between plasma protein and IgG N-glycosylation and antidiabetic therapy. Results: Our findings reveal that metformin, SGLT2 inhibitors, and GLP-1RA induce significant alterations in IgG glycosylation, including the increased core fucosylation and galactosylation, features associated with a reduced inflammatory IgG potential. Notably, IgG monogalactosylation, previously linked to cardioprotective effects in women, was elevated in response to GLP-1RA and SGLT2 inhibitor treatments. Plasma protein glycosylation changes were more limited, with distinct alterations observed for each therapy. Metformin and GLP-1RA similarly reduced certain fucosylated and sialylated glycans, while SGLT2 inhibitors decreased a high-mannose glycan, previously positively associated with diabetes progression. Insulin therapy had a minimal effect on protein glycosylation, with only one plasma glycan significantly altered. Conclusions: Our findings emphasise the importance of protein glycosylation as a dynamic and responsive marker in T2D treatment. The distinct glycan alterations observed in response to metformin, SGLT2 inhibitors, and GLP-1 receptor agonists provide novel insights into the molecular effects of these therapies, potentially contributing to the development of glycan-based biomarkers for personalized diabetes management. What is already known on this topic?: ✓ Protein glycosylation is known to regulate multiple processes related to glucose homeostasis. ✓ Previous studies have shown that the IgG and plasma protein N-glycome (the entire set of N-glycans covalently attached to the IgG and plasma proteins, respectively) can help identify individuals at increased cardiometabolic risk. ✓ Despite most T2D patients receiving antidiabetic treatment, research on its effects on protein glycosylation remains scarce. What this study adds?: ✓ It is the first study to explore the effects of SGLT2 inhibitor and GLP-1RA therapy on protein glycosylation. ✓ The cardioprotective effects of these drug classes were also reflected in IgG glycosylation, demonstrated by increased monogalactosylation. ✓ Metformin, SGLT2 inhibitors, and GLP-1RA induce significant increase in IgG core fucosylation, a feature associated with reduced inflammatory IgG potential, possibly suggesting a shared pathway in suppressing inflammatory response. How this study might affect research, practice or policy?: ✓ The observed alterations in protein glycosylation across different therapeutic groups highlight its dynamic nature in response to metabolic interventions. ✓ Given the role of glycans in modulating immune function and inflammation, these findings suggest that glycan alterations could serve as potential biomarkers for assessing therapeutic response and disease progression in T2D. ✓ Future studies involving protein glycosylation should account for the potential confounding effects of antidiabetic medications to ensure accurate interpretations.
- Open Access
- 23 April 2026
- Published by Springer Nature in Research Square
The Immunoglobulin G Glycome: A Modifiable Biomarker and Functional Effector of Aging, Disease, and Mortality
Glycosylation is a key structural modification of immunoglobulin G (IgG) that modulates its effector functions and has multiple roles in balancing inflammation. Altered IgG glycosylation has been reported in many diseases, often years before clinical manifestation, suggesting its causal role and biomarker potential. Here, we analyzed IgG glycome composition in 20,405 individuals from 42 different studies processed at the Genos Glycoscience Research Laboratory between 2008 and 2025. Across nearly all diseases, specific IgG glycome profiles reflected accelerated biological aging. Accelerated glycan aging was strongly associated with increased risk of all-cause mortality, independent of established clinical risk factors and potential confounders. Moreover, interventions known to reduce mortality risk, including hormone replacement therapy, therapeutic plasma exchange and caloric restriction, were associated with reversal of glycan aging. Given their role in modulating low-grade systemic inflammation, IgG glycans may represent a functional link between chronic inflammation, aging, disease susceptibility and all-cause mortality.
- 23 April 2026
- Published by Springer Nature in Research Square
Open AccessThe Immunoglobulin G Glycome: A Modifiable Biomarker and Functional Effector of Aging, Disease, and Mortality
Glycosylation is a key structural modification of immunoglobulin G (IgG) that modulates its effector functions and has multiple roles in balancing inflammation. Altered IgG glycosylation has been reported in many diseases, often years before clinical manifestation, suggesting its causal role and biomarker potential. Here, we analyzed IgG glycome composition in 20,405 individuals from 42 different studies processed at the Genos Glycoscience Research Laboratory between 2008 and 2025. Across nearly all diseases, specific IgG glycome profiles reflected accelerated biological aging. Accelerated glycan aging was strongly associated with increased risk of all-cause mortality, independent of established clinical risk factors and potential confounders. Moreover, interventions known to reduce mortality risk, including hormone replacement therapy, therapeutic plasma exchange and caloric restriction, were associated with reversal of glycan aging. Given their role in modulating low-grade systemic inflammation, IgG glycans may represent a functional link between chronic inflammation, aging, disease susceptibility and all-cause mortality.
- Open Access
Plasma glycome reflects low back pain progression and is not predictive of acute-to-chronic pain transition
Aims To investigate if the plasma N-glycome would provide a biomarker of acute-to-chronic low back pain (LBP) transition. Patients & Methods A prospective longitudinal sample of n = 1,114 individuals enrolled at the first ever episode of LBP and followed-up for three months. Total plasma N-glycome was measured and compared at the baseline and follow-up. Results Initial pro-inflammatory patterns of plasma N-glycome change to normal levels between baseline and follow-up in those who resolved from LBP, but not in those who remained at pain after three months. Baseline levels of N-glycans were not predictive of the risk of chronic LBP at follow-up. Conclusion Total plasma N-glycan levels may reflect ongoing inflammation that is aberrant and promotes ongoing pain and chronicity of symptoms.
Open AccessPlasma glycome reflects low back pain progression and is not predictive of acute-to-chronic pain transition
Aims To investigate if the plasma N-glycome would provide a biomarker of acute-to-chronic low back pain (LBP) transition. Patients & Methods A prospective longitudinal sample of n = 1,114 individuals enrolled at the first ever episode of LBP and followed-up for three months. Total plasma N-glycome was measured and compared at the baseline and follow-up. Results Initial pro-inflammatory patterns of plasma N-glycome change to normal levels between baseline and follow-up in those who resolved from LBP, but not in those who remained at pain after three months. Baseline levels of N-glycans were not predictive of the risk of chronic LBP at follow-up. Conclusion Total plasma N-glycan levels may reflect ongoing inflammation that is aberrant and promotes ongoing pain and chronicity of symptoms.
- Open Access
- 14 June 2024
- Published by Springer Nature in GeroScience
- Vol. 46 (6) , 5781-5796
Glycan clock of ageing—analytical precision and time-dependent inter- and i-individual variability
Ageing is a complex biological process with variations among individuals, leading to the development of ageing clocks to estimate biological age. Glycans, particularly in immunoglobulin G (IgG), have emerged as potential biomarkers of ageing, with changes in glycosylation patterns correlating with chronological age.For precision analysis, three different plasma pools were analysed over 26 days in tetraplicates, 312 samples in total. In short-term variability analysis, two cohorts were analysed: AstraZeneca MFO cohort of 26 healthy individuals (median age 20) and a cohort of 70 premenopausal Chinese women (median age 22.5) cohort monitored over 3 months. Long-term variability analysis involved two adult men aged 47 and 57, monitored for 5 and 10 years, respectively. Samples were collected every 3 months and 3 weeks, respectively. IgG N-glycan analysis followed a standardized approach by isolating IgG, its subsequent denaturation and deglycosylation followed by glycan cleanup and labelling. Capillary gel electrophoresis with laser-induced fluorescence (CGE-LIF) and ultra-performance liquid chromatography analyses were employed for glycan profiling. Statistical analysis involved normalization, batch correction, and linear mixed models to assess time effects on derived glycan traits.The intermediate precision results consistently exhibited very low coefficient of variation values across all three test samples. This consistent pattern underscores the high level of precision inherent in the CGE method for analysing the glycan clock of ageing. The AstraZeneca MFO cohort did not show any statistically significant trends, whereas the menstrual cycle cohort exhibited statistically significant trends in digalactosylated (G2), agalactosylated (G0) and fucosylation (F). These trends were attributed to the effects of the menstrual cycle. Long-term stability analysis identified enduring age-related trends in both subjects, showing a positive time effect in G0 and bisected N-acetylglucosamine, as well as a negative time effect in G2 and sialylation, aligning with earlier findings. Time effects measured for monogalactosylation, and F remained substantially lower than ones observed for other traits.The study found that IgG N-glycome analysis using CGE-LIF exhibited remarkably high intermediate precision. Moreover, the study highlights the short- and long-term stability of IgG glycome composition, coupled with a notable capacity to adapt and respond to physiological changes and environmental influences such as hormonal changes, disease, and interventions. The discoveries from this study propel personalized medicine forward by deepening our understanding of how IgG glycome relates to age-related health concerns. This study underscores the reliability of glycans as a biomarker for tracking age-related changes and individual health paths.
- 14 June 2024
- Published by Springer Nature in GeroScience
- Vol. 46 (6) , 5781-5796
Open AccessGlycan clock of ageing—analytical precision and time-dependent inter- and i-individual variability
Ageing is a complex biological process with variations among individuals, leading to the development of ageing clocks to estimate biological age. Glycans, particularly in immunoglobulin G (IgG), have emerged as potential biomarkers of ageing, with changes in glycosylation patterns correlating with chronological age.For precision analysis, three different plasma pools were analysed over 26 days in tetraplicates, 312 samples in total. In short-term variability analysis, two cohorts were analysed: AstraZeneca MFO cohort of 26 healthy individuals (median age 20) and a cohort of 70 premenopausal Chinese women (median age 22.5) cohort monitored over 3 months. Long-term variability analysis involved two adult men aged 47 and 57, monitored for 5 and 10 years, respectively. Samples were collected every 3 months and 3 weeks, respectively. IgG N-glycan analysis followed a standardized approach by isolating IgG, its subsequent denaturation and deglycosylation followed by glycan cleanup and labelling. Capillary gel electrophoresis with laser-induced fluorescence (CGE-LIF) and ultra-performance liquid chromatography analyses were employed for glycan profiling. Statistical analysis involved normalization, batch correction, and linear mixed models to assess time effects on derived glycan traits.The intermediate precision results consistently exhibited very low coefficient of variation values across all three test samples. This consistent pattern underscores the high level of precision inherent in the CGE method for analysing the glycan clock of ageing. The AstraZeneca MFO cohort did not show any statistically significant trends, whereas the menstrual cycle cohort exhibited statistically significant trends in digalactosylated (G2), agalactosylated (G0) and fucosylation (F). These trends were attributed to the effects of the menstrual cycle. Long-term stability analysis identified enduring age-related trends in both subjects, showing a positive time effect in G0 and bisected N-acetylglucosamine, as well as a negative time effect in G2 and sialylation, aligning with earlier findings. Time effects measured for monogalactosylation, and F remained substantially lower than ones observed for other traits.The study found that IgG N-glycome analysis using CGE-LIF exhibited remarkably high intermediate precision. Moreover, the study highlights the short- and long-term stability of IgG glycome composition, coupled with a notable capacity to adapt and respond to physiological changes and environmental influences such as hormonal changes, disease, and interventions. The discoveries from this study propel personalized medicine forward by deepening our understanding of how IgG glycome relates to age-related health concerns. This study underscores the reliability of glycans as a biomarker for tracking age-related changes and individual health paths.
- Open Access
Effects of testosterone and metformin on the GlycanAge index of biological age and the composition of the IgG glycome
With aging, there is a correlation between a decline in the body’s ability to maintain regular functioning and greater susceptibility to age-related diseases. Therapeutic interventions targeting the underlying biological changes of aging hold promise for preventing or delaying multiple age-related diseases. Metformin, a drug commonly used for diabetes treatment, has emerged as a potential gerotherapeutic agent due to its established safety record and preclinical and clinical data on its anti-aging effects. Glycosylation, one of the most common and complex co- and post-translational protein modifications, plays a crucial role in regulating protein function and has been linked to aging and various diseases. Changes in IgG glycosylation patterns have been observed with age, and these alterations may serve as valuable biomarkers for disease predisposition, diagnosis, treatment monitoring, and overall health assessment. In this study, we analyzed the IgG glycosylation patterns of individuals under treatment with metformin, testosterone, metformin plus testosterone and placebo, and investigated the longitudinal changes in glycosylation over time. We observed statistically significant differences in the IgG glycome composition between participants on testosterone therapy and placebo, with decreased agalactosylation and increased galactosylation and sialylation. However, metformin therapy did not result in statistically significant changes in glycosylation patterns. These findings contribute to our understanding of the impact of therapeutic interventions on IgG glycosylation and confirm the value of IgG glycosylation as a significant biomarker, capable of assessing biological age using the GlycanAge index and providing insight into overall health compared to chronological age.
Open AccessEffects of testosterone and metformin on the GlycanAge index of biological age and the composition of the IgG glycome
With aging, there is a correlation between a decline in the body’s ability to maintain regular functioning and greater susceptibility to age-related diseases. Therapeutic interventions targeting the underlying biological changes of aging hold promise for preventing or delaying multiple age-related diseases. Metformin, a drug commonly used for diabetes treatment, has emerged as a potential gerotherapeutic agent due to its established safety record and preclinical and clinical data on its anti-aging effects. Glycosylation, one of the most common and complex co- and post-translational protein modifications, plays a crucial role in regulating protein function and has been linked to aging and various diseases. Changes in IgG glycosylation patterns have been observed with age, and these alterations may serve as valuable biomarkers for disease predisposition, diagnosis, treatment monitoring, and overall health assessment. In this study, we analyzed the IgG glycosylation patterns of individuals under treatment with metformin, testosterone, metformin plus testosterone and placebo, and investigated the longitudinal changes in glycosylation over time. We observed statistically significant differences in the IgG glycome composition between participants on testosterone therapy and placebo, with decreased agalactosylation and increased galactosylation and sialylation. However, metformin therapy did not result in statistically significant changes in glycosylation patterns. These findings contribute to our understanding of the impact of therapeutic interventions on IgG glycosylation and confirm the value of IgG glycosylation as a significant biomarker, capable of assessing biological age using the GlycanAge index and providing insight into overall health compared to chronological age.
- Open Access
- 27 June 2022
- Published by Elsevier in EBioMedicine
- Vol. 81, 104101
IgG N-glycome changes during the course of severe COVID-19: An observational study
- 27 June 2022
- Published by Elsevier in EBioMedicine
- Vol. 81, 104101
Open AccessIgG N-glycome changes during the course of severe COVID-19: An observational study
- Open Access
- 20 September 2021
- Published by Springer Nature in Glycoconjugate Journal
- Vol. 38 (5) , 611-623
SARS-CoV-2 S glycoprotein binding to multiple host receptors enables cell entry and infection
The severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) infection displays a wide array of clinical manifestations. Although some risk factors for coronavirus disease 2019 (COVID-19) severity and outcomes have been identified the underlying biologic mechanisms are still not well understood. The surface SARS-CoV-2 proteins are heavily glycosylated enabling host cell interaction and viral entry. Angiotensin-converting enzyme 2 (ACE2) has been identified to be the main host cell receptor enabling SARS-CoV-2 cell entry after interaction with its S glycoprotein. However, recent studies report SARS-CoV-2 S glycoprotein interaction with other cell receptors, mainly C-type lectins which recognize specific glycan epitopes facilitating SARS-CoV-2 entry to susceptible cells. Here, we are summarizing the main findings on SARS-CoV-2 interactions with ACE2 and other cell membrane surface receptors and soluble lectins involved in the viral cell entry modulating its infectivity and potentially playing a role in subsequent clinical manifestations of COVID-19. Graphical abstract
- 20 September 2021
- Published by Springer Nature in Glycoconjugate Journal
- Vol. 38 (5) , 611-623
Open AccessSARS-CoV-2 S glycoprotein binding to multiple host receptors enables cell entry and infection
The severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) infection displays a wide array of clinical manifestations. Although some risk factors for coronavirus disease 2019 (COVID-19) severity and outcomes have been identified the underlying biologic mechanisms are still not well understood. The surface SARS-CoV-2 proteins are heavily glycosylated enabling host cell interaction and viral entry. Angiotensin-converting enzyme 2 (ACE2) has been identified to be the main host cell receptor enabling SARS-CoV-2 cell entry after interaction with its S glycoprotein. However, recent studies report SARS-CoV-2 S glycoprotein interaction with other cell receptors, mainly C-type lectins which recognize specific glycan epitopes facilitating SARS-CoV-2 entry to susceptible cells. Here, we are summarizing the main findings on SARS-CoV-2 interactions with ACE2 and other cell membrane surface receptors and soluble lectins involved in the viral cell entry modulating its infectivity and potentially playing a role in subsequent clinical manifestations of COVID-19. Graphical abstract